首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Use of Microdilution Panels with and without β-Lactamase Inhibitors as a Phenotypic Test for β-Lactamase Production among Escherichia coli Klebsiella spp. Enterobacter spp. Citrobacter freundii and Serratia marcescens
【2h】

Use of Microdilution Panels with and without β-Lactamase Inhibitors as a Phenotypic Test for β-Lactamase Production among Escherichia coli Klebsiella spp. Enterobacter spp. Citrobacter freundii and Serratia marcescens

机译:具有和不具有β-内酰胺酶抑制剂的微稀释板在大肠杆菌克雷伯菌肠杆菌弗氏柠檬酸杆菌和粘质沙雷氏菌中的β-内酰胺酶生产的表型测试中的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Over the past decade, a number of new β-lactamases have appeared in clinical isolates of Enterobacteriaceae that, unlike their predecessors, do not confer β-lactam resistance that is readily detected in routine antibiotic susceptibility tests. Because optimal methodologies are needed to detect these important new β-lactamases, a study was designed to evaluate the ability of a panel of various β-lactam antibiotics tested alone and in combination with β-lactamase inhibitors to discriminate between the production of extended-spectrum β-lactamases, AmpC β-lactamases, high levels of K1 β-lactamase, and other β-lactamases in 141 isolates of Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, Enterobacter aerogenes, Citrobacter freundii, and Serratia marcescens possessing well-characterized β-lactamases. The microdilution panels studied contained aztreonam, cefpodoxime, ceftazidime, cefotaxime, and ceftriaxone, with and without 1, 2, and 4 μg of clavulanate per ml or 8 μg of sulbactam per ml and cefoxitin and cefotetan with and without 8 μg of sulbactam per ml. The results indicated that a minimum panel of five tests would provide maximum separation of extended-spectrum β-lactamase high AmpC, high K1, and other β-lactamase production in Enterobacteriaceae. These included cefpodoxime, cefpodoxime plus 4 μg of clavulanate per ml, ceftazidime, ceftriaxone, and ceftriaxone plus 8 μg of sulbactam per ml. Ceftriaxone plus 2 μg of clavulanate per ml could be substituted for cefpodoxime plus 4 μg of clavulanate per ml without altering the accuracy of the tests. This study indicated that tests with key β-lactam drugs, alone and in combination with β-lactamase inhibitors, could provide a convenient approach to the detection of a variety of β-lactamases in members of the family Enterobacteriaceae.
机译:在过去的十年中,肠杆菌科的临床分离物中出现了许多新的β-内酰胺酶,与它们的前代菌株不同,它们不具有在常规抗生素敏感性试验中容易检测到的β-内酰胺抗性。由于需要最佳方法来检测这些重要的新β-内酰胺酶,因此设计了一项研究,以评估一组单独测试并与β-内酰胺酶抑制剂联合测试的各种β-内酰胺抗生素区分扩谱产生的能力。 β-内酰胺酶,AmpCβ-内酰胺酶,高水平的K1β-内酰胺酶和其他β-内酰胺酶在141株大肠杆菌,肺炎克雷伯菌,产氧克雷伯菌,阴沟肠杆菌,产气肠杆菌,弗氏柠檬酸杆菌和粘质沙雷氏菌中分离出表征的β-内酰胺酶。所研究的微稀释板包含氨曲南,头孢泊肟,头孢他啶,头孢噻肟和头孢曲松,每毫升含1、2和4克克拉维酸,每毫升含8克舒巴坦,每毫升含头孢西丁和头孢替坦,每毫升含或不含有8克舒巴坦。结果表明,最少要进行五项测试,才能最大程度地分离肠杆菌科细菌中广谱β-内酰胺酶,高AmpC,高K1和其他β-内酰胺酶。其中包括头孢泊肟,头孢泊肟每毫升加4μg克拉维酸盐,头孢他啶,头孢曲松和头孢曲松钠每毫升加8微克舒巴坦。头孢曲松加每毫升2微克的克拉维酸盐可以代替头孢泊肟加每毫升4微克的克拉维酸盐,而不会改变测试的准确性。这项研究表明,单独使用关键的β-内酰胺药物或与β-内酰胺酶抑制剂联合使用,可以为检测肠杆菌科成员的各种β-内酰胺酶提供便利的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号